By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


NeuroDerm Ltd. 

Ofakim      Israel
Phone: 925-270-0519 Fax: 925-290-1209



Company News
NeuroDerm Ltd. (NDRM) To Announce Updated Topline Results Of Phase II Study Of Continuous, Subcutaneously-Delivered Levodopa/Carbidopa For The Treatment Of Parkinson's Disease At The 67th Annual Meeting Of The American Academy of Neurology 4/1/2015 6:10:40 AM
NeuroDerm Ltd. (NDRM) CEO To Present At Upcoming Investor Conferences 2/24/2015 9:00:09 AM
NeuroDerm Ltd. (NDRM) Announces Extraordinary General Meeting Of Shareholders For Ratification Of Election Of External Directors And Adoption Of Compensation Policy 1/20/2015 6:03:08 AM
NeuroDerm Ltd. (NDRM) Announces Topline Results Of Phase 2a Pharmacokinetic Study Of ND0612H And ND0612L, Continuous, Subcutaneously Delivered Levodopa/Carbidopa For The Treatment Of Parkinson's Disease 12/31/2014 6:41:09 AM
NeuroDerm Ltd. (NDRM) Shares Double as Parkinson's Drug Shows Promise in Phase 2 Study 12/30/2014 7:21:51 AM
NeuroDerm Ltd. (NDRM) Announces Third Quarter 2014 Financial Results And Provides A Corporate Update 12/18/2014 8:00:07 AM
NeuroDerm Ltd. (NDRM) CEO To Present At Oppenheimer Healthcare Conference On December 10, 2014 12/8/2014 8:13:10 AM
NeuroDerm Ltd. (NDRM) IPO Disappoints 11/14/2014 7:27:53 AM
NeuroDerm Ltd. Announces Presentation Of ND0612L Top-Line Phase 2 Results And ND0612H Preliminary Interim Phase 2a Results At The 2014 Parkinson's Disease Therapeutics Conference 10/23/2014 7:26:35 AM
Israeli Biotech NeuroDerm Ltd. Files For $65 Million IPO 9/16/2014 6:56:34 AM